Effects of Topical Lidocaine and Benzocaine on Pain Level and Injection Satisfaction

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-06-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Design: factorial (lowers risk) · Design
• Drug's FAERS reports marked serious: 58.7% (lowers risk) · Drug's FDA history
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: alzheimertopicalas epilepsyplanningpregnancy
  Phrases that lowered it: painparticipantsevaluate theto evaluatespray
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 67 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.1% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Primary purpose: supportive care (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Sponsor's past trials: 125 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 93247 (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Blinding: double (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Effect of Lidocaine and Benzocaine on Pain and Injection Satisfaction in Peripheral Intravenous Catheter Application NCT04859738 · started 2020 · scored riskier than 6% of active trials completed
• Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis NCT01382888 · started 2011 · scored riskier than 54% of active trials terminated
• Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis NCT02335099 · started 2014 · scored riskier than 42% of active trials completed
• A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1) NCT02110901 · started 2014 · scored riskier than 80% of active trials completed
• A Study to Assess the Ability of 2% Lidocaine Gel to Reduce the Discomfort of Urethral Catheterization NCT01690767 · started 2011 · scored riskier than 60% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.